Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | ESR1 | P03372 | 4/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4017819 | 0.93 | MEN1 (0.47) | MMP1MMP2MMP9MEN1KMT2A | |
| SCHEMBL4017820 | 0.92 | MAPT (0.50) | MEN1KMT2A | |
| SCHEMBL4017823 | 0.92 | MAPT (0.50) | MEN1KMT2A | |
| SCHEMBL13982589 | 0.91 | MEN1 (0.43) | MMP1MMP2MMP9MEN1KMT2A | |
| SCHEMBL4016316 | 0.91 | MEN1 (0.43) | MMP1MMP2MMP9MEN1KMT2A | |
| SCHEMBL4017825 | 0.91 | MMP1 (0.50) | MMP1MMP2MMP9MEN1KMT2A | |
| SCHEMBL4667914 | 0.91 | BACE1 (0.43) | MMP1MMP2MMP9BCHEACHE | |
| SCHEMBL4752215 | 0.90 | MEN1 (0.43) | MMP1MMP2MMP9MEN1KMT2A | |
| SCHEMBL4668502 | 0.90 | MEN1 (0.43) | MMP1MMP2MMP9MEN1KMT2A | |
| SCHEMBL4015839 | 0.90 | MEN1 (0.44) | MMP1MMP2MMP9ACHEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2014287-A1 | Use of cinnamic acid derivatives as modulators of an EP2 receptor | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-01-14 | — | — | EP | claimed |
| EP-2014287-A1 | Use of cinnamic acid derivatives as modulators of an EP2 receptor | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-01-14 | — | — | EP | disclosed |